Eli Lilly adds a $15M equity sweetener for its platform partner in saRNA
The father-and-son team at MiNA Therapeutics is on a roll.
Just weeks after snagging a $25 million upfront and a treasure map with close to $1.25 billion in milestones from Eli Lilly, the pharma giant is back with a $15 million equity sweetener.
A quiet player for the first decade of its existence, MiNA Therapeutics has been racking up deals and dollars in the past 2 years. In addition to the Lilly pact, AstraZeneca signed up with the Imperial College London spinout along with Servier.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.